dataset
posted on 2023-03-31, 15:21 authored by Heather L. McArthur, Clifford A. Hudis Related Article from Trastuzumab: A Picky Partner?
History
ARTICLE ABSTRACT
Preclinical and clinical models of HER2-positive breast cancer show that human epidermal growth factor receptor 2 (HER2)-targeted therapy with trastuzumab adds significant benefits and modest risks to conventional cytotoxic therapies. Building on this advance will likely depend on elucidation of relevant signaling pathways and mechanisms of action for effective HER2-targeted therapies. (Clin Cancer Res 2009;15(20):6311–3)
